SCIENTIFIC POSTER 2016_Comparison of the Effect of Ranibizumab and Aflibercept for Choroidal Thickness Changes in Wet AMD Hee Seong Yoon

Purpose:

To compare the changes in subfoveal choroidal thickness (SFCT) after intravitreal ranibizumab or aflibercept injections for neovascular age-related macular degeneration (nAMD).

Methods:

Medical records of 67 treatment-naive patients (69 eyes) who were diagnosed with neovascular AMD (nAMD) and received three monthly injections of ranibizumab (38 eyes) or aflibercept (31 eyes) were reviewed. All patients included in the study showed complete resolu tion after 3 loading injections and maintained the state during at least 6-month follow-up period. Subfoveal choroidal thickness (SFCT) at baseline, 3 months, and 6 months was measured by enhanced depth imaging optical coherence tomography (EDI-OCT). Periodic changes of SFCT were compared between ranibizumab and aflibercept group. By extension, we classified all study eyes into three subtypes: typical nAMD, polypoidal choroidal vasculopathy (PCV) and retinal angiomatous proliferation (RAP), and compared the changes of SFCT between two drug groups for each subtype. The changes of BCVA and CMT were also compared between the two drug groups.

Results:

Subfoveal choroidal thickness (SFCT) significantly decreased over time in both groups. At each time point, the percentage of SFCT change was greater in aflibercept group compared with ranibizumab group, but there was no significant difference between two groups. The changes of BCVA and CMT did not show significant difference between two groups. There was significant difference in baseline SFCT among three subtypes of AMD. Baseline SFCT decreased significantly in PCV, typical nAMD and RAP, in that order. For the eyes with typical nAMD and RAP, there was no significant difference in the percentage of SFCT change between two drug groups. However, in PCV, the aflibercept group significantly exihibited greater decrease in the percentage of SFCT change compared with ranibizumab group. There was no correlation between the amount of change in SFCT and age, sex, number of injections, baseline BCVA, CMT and OCT characteristics including intraretinal cystoid fluid, subretinal fluid and pigment epithelial detachment. Only the basline SFCT showed significant positive correlation with the amount of SFCT change in aflibercept group.

Conclusions:

There was no significant difference in the percentage of SFCT change between ranibizumab and aflibercept group. In the analysis according to subtypes, intravitreally injected aflibercept eyes significantly showed greater decrease in SFCT change compared with ranibizumab the in PCV. Thicker baseline SFCT of PCV might be associated with greater amount of SFCT change after aflibercept injection.

Contact Details:

Email: heesyoon@dreamwiz.com
Cell Phone: +821096999467

Hee Seong Yoon